Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma|Carcinoma of Unknown Primary|Endometrial Carcinoma|Esophageal Carcinoma|Liver Failure|Lung Carcinoma|Malignant Head and Neck Neoplasm|Malignant Testicular Neoplasm|Melanoma|Metastatic Malignant Neoplasm|Ovarian Carcinoma|Renal Failure|Unresectable Malignant Neoplasm|Urothelial Carcinoma
Interventions: DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Pharmacological Study|DRUG: Veliparib
Sponsor: National Cancer Institute (NCI)
Collaborators: Abbott